
Hi Doctors, I Went To A Breast Cancer Conference And

Hello. as of now there is no data
Detailed Answer:
Hello XXXXXXX Welcome to HCM. I understand your concern being a brave cancer survivor.
So definitely, extended tamoxifen offers advantage in terms of preventing a relapse. As of now , we have data for 10 years but at the marginally increased cost of carcinoma endometrium. Anastrazole and letrozole are better in this regard as the side effect profile is better. After 10 years, theoretically speaking , more tamoxifen and anastrazole/letrozole should offer more protection . But then medicine is based on evidences and we dont have a fifteen year data now. Sooner the evidence is there, it will get incorporated into guidelines. There is no harm , but i will advise anastrazole/letrozole as compared to tamoxifen for you.
Thanks and regards


Hello. raloxifene(evista) is less effective
Detailed Answer:
Hello dear. So raloxifene is less effective as compared to tamoxifen or anastrazole/letrozole for the prevention. As per guidelines , we dont offer raloxifene to our patients.
Thanks and regards

Answered by

Get personalised answers from verified doctor in minutes across 80+ specialties
